Drug-Induced AKI: Mechanism Before Label

Several injury pathways

Medications can alter glomerular hemodynamics, directly injure tubules, trigger interstitial inflammation, or precipitate crystals. Some raise creatinine through reduced tubular secretion without reducing filtration; others cause genuine injury.

Recognize the exposure pattern

Look for a new prescription, dose increase, prolonged treatment, interacting drugs, or a dehydrating illness. Include over-the-counter analgesics, acid suppressants, supplements, and recent contrast exposure in the history.

Build a timeline

Compare drug start dates with creatinine, urine output, electrolyte changes, and symptoms. Examine urine and assess volume status. Consider drug concentrations when a validated monitoring strategy exists for that agent.

Reduce preventable harm

Use the appropriate indication, renal dosing, shortest effective course, and laboratory follow-up. Coordinate with pharmacy when kidney function changes rapidly or the patient receives kidney replacement therapy.

Respond to suspected toxicity

Stop or substitute the likely culprit when feasible, support circulation, and treat complications. Infection may still require effective antimicrobial coverage. Document the suspected mechanism and plan for recovery monitoring.

Avoid class-wide assumptions

Risk varies with dose, duration, patient physiology, and coexposures. Association does not prove causation. A creatinine rise during protective therapy needs clinical interpretation before a useful medication is permanently abandoned.

Self-check: Separate hemodynamic effects, direct toxicity, interstitial inflammation, and altered creatinine secretion before deciding whether the same management fits every medication-related rise.